Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway

The phosphoinositide 3-kinase pathway

Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621

PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer

Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785

AMPK: a nutrient and energy sensor that maintains energy homeostasis

Hardie, D. G., Ross, F. A., & Hawley, S. A. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3311 · Cited by 4,602

Cellular survival: a play in three Akts

Datta, S. R., Brunet, A., & Greenberg, M. E. (1999) · Genes & Development · doi:10.1101/gad.13.22.2905 · Cited by 4,216

Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma

Hudes, G. R., Carducci, M. A., Tomczak, P., Dutcher, J. P., Figlin, R. A., Kapoor, A., Starosławska, E., Sosman, J. A., McDermott, D. F., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,645

High Frequency of Mutations of the PIK3CA Gene in Human Cancers

Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A. F., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,448

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330

The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate

Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

Yao, J. C., Shah, M. H., Ito, T., Lombard‐Bohas, C., Wolin, E. M., Cutsem, E. V., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,879

Antioxidant Activity and Neuroprotective Activity of Stilbenoids in Rat Primary Cortex Neurons via the PI3K/Akt Signalling Pathway

Wen, H., Fu, Z., Wei, Y., Zhang, X., Ma, L., Gu, L., & Li, J. (2018) · Molecules · doi:10.3390/molecules23092328 · Cited by 40

Silencing of FOXO6 inhibits the proliferation, invasion, and glycolysis in colorectal cancer cells

Li, Q., Tang, H., Hu, F., & Qin, C. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27667 · Cited by 40

Study on the mechanism of Fufang E'jiao Jiang on precancerous lesions of gastric cancer based on network pharmacology and metabolomics

Shi, W., Wang, Z., Liu, H., Jia, Y.-J., Wang, Y., Xu, X., Zhang, Y., Qi, X., & Hu, F. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.116030 · Cited by 39

Dual blocking of PI3K and mTOR signaling by NVP-BEZ235 inhibits proliferation in cervical carcinoma cells and enhances therapeutic response

Xie, G., Wang, Z., Chen, Y., Zhang, S., Lu, F., Meng, F., & Yu, Z. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.11.024 · Cited by 39

Novel PI3K/Akt/mTOR signaling inhibitor, W922, prevents colorectal cancer growth via the regulation of autophagy

Wang, J., Dong, L., Zhang, X., He, C., Cao, L., Zhang, S., Xiao, X., Li, S., & Cao, Y. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5151 · Cited by 41

Resveratrol induces cell apoptosis in adipocytes via AMPK activation

Chen, S., Zhou, N., Zhang, Z., Li, W., & Zhu, W. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.01.034 · Cited by 39

An Anti‐Cancer Drug Candidate OSI‐027 and its Analog as Inhibitors of mTOR: Computational Insights Into the Inhibitory Mechanisms

Rehan, M. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26117 · Cited by 39

Integrin-α5 promoted the progression of oral squamous cell carcinoma and modulated PI3K/AKT signaling pathway

Fan, Q., Tian, H., Wang, Y., & Liu, X.-B. (2019) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2019.03.007 · Cited by 38

Mechanisms of Resistance to Checkpoint Blockade Therapy

Shi, H., Lan, J., & Yang, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_5 · Cited by 37

LncRNA LINC01857 promotes cell growth and diminishes apoptosis via PI3K/mTOR pathway and EMT process by regulating miR-141-3p/MAP4K4 axis in diffuse large B-cell lymphoma

Li, Q., Bao, L., Lu, C., Wang, J., Gao, M., & Gao, W. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-00267-4 · Cited by 38

Alnustone inhibits the growth of hepatocellular carcinoma via ROS ‐ mediated PI3K /Akt/ mTOR / p70S6K axis

Wang, L., Cheng, L., Ma, L., Farooqı, A. A., Qiao, G., Zhang, Y., Ye, H., Liu, M., Huang, J., Yang, X., et al. (2021) · Phytotherapy Research · doi:10.1002/ptr.7337 · Cited by 40

Mechanically activated ion channel Piezo1 contributes to melanoma malignant progression through AKT/mTOR signaling

Zhang, S., Cao, S., Gong, M., Zhang, W., Zhang, W., Zhu, Z., Wu, S., Yue, Y., wang, L., yue, Y., et al. (2022) · Cancer Biology & Therapy · doi:10.1080/15384047.2022.2060015 · Cited by 42

METTL3-IGF2BP3-axis mediates the proliferation and migration of pancreatic cancer by regulating spermine synthase m6A modification

Guo, Z., Zhang, X., Lin, C., Huang, Y., Zhong, Y., Guo, H., Zhou, Z., & Weng, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.962204 · Cited by 37

Oridonin upregulates PTEN through activating p38 MAPK and inhibits proliferation in human colon cancer cells

Wu, Q., YUAN, S.-X., REN, C.-M., YU, Y., Sun, W., He, B., & Wu, K. (2016) · Oncology Reports · doi:10.3892/or.2016.4735 · Cited by 37

PI3K/mTOR Dual Inhibitor, LY3023414, Demonstrates Potent Antitumor Efficacy Against Esophageal Adenocarcinoma in a Rat Model

Zaidi, A. H., Kosovec, J. E., Matsui, D., Omstead, A. N., Raj, M. S., Rao, R. R., Biederman, R. W., Finley, G. G., Landreneau, R. J., Kelly, R. J., et al. (2016) · Annals of Surgery · doi:10.1097/sla.0000000000001908 · Cited by 37

Staurosporine suppresses survival of HepG2 cancer cells through Omi/HtrA2-mediated inhibition of PI3K/Akt signaling pathway

Ding, Y., Wang, B., Chen, X., Zhou, Y., & Ge, J. (2017) · Tumor Biology · doi:10.1177/1010428317694317 · Cited by 37

Synergistic Interplay between Curcumin and Polyphenol-Rich Foods in the Mediterranean Diet: Therapeutic Prospects for Neurofibromatosis 1 Patients

Esposito, T., Schettino, C., Polverino, P., Allocca, S., Adelfi, L., D’Amico, A., Capaldo, G., Varriale, B., Salle, A. D., Peluso, G., et al. (2017) · Nutrients · doi:10.3390/nu9070783 · Cited by 37

Downregulation of kynureninase restrains cutaneous squamous cell carcinoma proliferation and represses the PI3K/AKT pathway

Ci, C., Wu, C., Lyu, D., Chang, X., He, C., Liu, W. Y., Chen, L., & Ding, W. (2019) · Clinical and Experimental Dermatology · doi:10.1111/ced.14072 · Cited by 37

Inhibition of PHLPP1 ameliorates cardiac dysfunction via activation of the PI3K/Akt/mTOR signalling pathway in diabetic cardiomyopathy

Zhang, M., Wang, X., Liu, M., Liu, D., Pan, J., Tian, J., Jin, T., Xu, Y., & An, F. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15123 · Cited by 37

α-Hederin inhibits the growth of lung cancer A549 cells in vitro and in vivo by decreasing SIRT6 dependent glycolysis

Fang, C., Liu, Y., Chen, L., Luo, Y., Cui, Y., Zhang, N., Liu, P., Zhou, M., & Xie, Y. (2020) · Pharmaceutical Biology · doi:10.1080/13880209.2020.1862250 · Cited by 38

mTOR pathway and DNA damage response: A therapeutic strategy in cancer therapy

Pazhooh, R. D., Farnood, P. R., Asemi, Z., Mirsafaei, L., Yousefi, B., & Mirzaei, H. (2021) · DNA repair · doi:10.1016/j.dnarep.2021.103142 · Cited by 36

The Heterogeneity of Lipid Metabolism in Cancer

Park, J. K., Coffey, N. J., Limoges, A., & Le, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-65768-0_3 · Cited by 38

Anti-proliferative effect of RCE-4 from Reineckia carnea on human cervical cancer HeLa cells by inhibiting the PI3K/Akt/mTOR signaling pathway and NF-κB activation

Bai, C.-H., Yang, X., Zou, K., He, H., Wang, J., Qin, H.-L., Yu, X., Liu, C., Zheng, J., Cheng, F., et al. (2016) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-016-1217-7 · Cited by 37

SAMHD1 modulates in vitro proliferation of acute myeloid leukemia-derived THP-1 cells through the PI3K-Akt-p27 axis

Kodigepalli, K. M., Bonifati, S., Tirumuru, N., & Wu, L. J. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1480218 · Cited by 36

The Different Conformational States of Tissue Transglutaminase Have Opposing Affects on Cell Viability

Singh, G., Zhang, J., Ma, Y., Cerione, R. A., & Antonyak, M. A. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.699108 · Cited by 36

Viral vector: potential therapeutic for glioblastoma multiforme

Manikandan, C., Kaushik, A., & Sen, D. (2019) · Cancer Gene Therapy · doi:10.1038/s41417-019-0124-8 · Cited by 37

MEX3A knockdown inhibits the development of pancreatic ductal adenocarcinoma

Wang, X., Shan, Y., Tan, Q., Tan, C., Zhang, H., Liu, J.-H., Ke, N., Chen, Y., & Liu, X.-B. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1146-x · Cited by 36

How can we turn the PI3K/AKT/mTOR pathway down? Insights into inhibition and treatment of cancer

Afify, S. M., Oo, A. K. K., Hassan, G., Seno, A., & Seno, M. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1918001 · Cited by 36

Genetic polymorphisms ofmTORand cancer risk: a systematic review and updated meta-analysis

Zining, J., Xu, L., He, C., & Yuan, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.10805 · Cited by 35

Cryptotanshinone inhibition of mammalian target of rapamycin pathway is dependent on oestrogen receptor alpha in breast cancer

Pan, Y., Shi, J., Ni, W., Liu, Y., Wang, S., Wang, X., Wei, Z., Wang, A., Chen, W., & Lu, Y. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13135 · Cited by 35

Chemokine ( CC motif) ligand 18 upregulates Slug expression to promote stem‐cell like features by activating the mammalian target of rapamycin pathway in oral squamous cell carcinoma

Wang, H., Liang, X., Li, M., Tao, X., Tai, S., Fan, Z., Wang, Z., Cheng, B., & Xia, J. (2017) · Cancer Science · doi:10.1111/cas.13289 · Cited by 35

Discovery of a Novel Series of 7-Azaindole Scaffold Derivatives as PI3K Inhibitors with Potent Activity

Yang, C., Zhang, X., Wang, Y., Yang, Y., Liu, X., Deng, M., Yu, J., Ling, Y., Meng, L., & Zhou, Y. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00222 · Cited by 35

Immuno-Matrix-Assisted Laser Desorption/Ionization Assays for Quantifying AKT1 and AKT2 in Breast and Colorectal Cancer Cell Lines and Tumors

Popp, R., Li, H., LeBlanc, A. M., Mohammed, Y., Aguilar‐Mahecha, A., Chambers, A. G., Lan, C., Poetz, O., Basik, M., Batist, G., et al. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b02934 · Cited by 34

Up-regulation of Rho-associated kinase 1/2 by glucocorticoids promotes migration, invasion and metastasis of melanoma

Huang, G.-X., Wang, Y., Su, J., Zhou, P., Li, B., Yin, L.-J., & Lu, J. G. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.005 · Cited by 35

GH and GHR signaling in human disease

Guevara‐Aguirre, J., Guevara, A., Palacios, I., Pérez, M. Q., Prócel, P., & Terán, E. (2017) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2017.12.006 · Cited by 35

KT2 and RT2 modified antimicrobial peptides derived from Crocodylus siamensis Leucrocin I show activity against human colon cancer HCT-116 cells

Maijaroen, S., Jangpromma, N., Daduang, J., & Klaynongsruang, S. (2018) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2018.07.007 · Cited by 38

Long Non-Coding RNA TTN-AS1 Promotes the Proliferation and Invasion of Colorectal Cancer Cells by Activating miR-497-Mediated PI3K/Akt/mTOR Signaling

Cui, Z., Han, B., Wang, X., Li, Z., Wang, J., & Lv, Y. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s229104 · Cited by 35

Arctigenin Inhibits Glioblastoma Proliferation through the AKT/mTOR Pathway and Induces Autophagy

Jiang, Y., Liu, J., Hong, W., Fei, X., & Liu, R. (2020) · BioMed Research International · doi:10.1155/2020/3542613 · Cited by 35

Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Jankú, F., Park, H., Call, S. G., Madwani, K., Oki, Y., Subbiah, V., Hong, D. S., Naing, A., Velez-Bravo, V. M., Barnes, T. G., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1215 · Cited by 35

Molecular Targets and Nanoparticulate Systems Designed for the Improved Therapeutic Intervention in Glioblastoma Multiforme

Akhter, M. H., Rizwanullah, M., Ahmad, J., Amin, S., Ahmad, M. Z., Minhaj, M. A., Mujtaba, M. A., & Ali, J. (2020) · Drug Research · doi:10.1055/a-1296-7870 · Cited by 35

TNFα Signaling Regulates Cystic Epithelial Cell Proliferation through Akt/mTOR and ERK/MAPK/Cdk2 Mediated Id2 Signaling

Zhou, J. X., Fan, L. X., Li, X., Calvet, J. P., & Li, X. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131043 · Cited by 36

BRAF and MEK Targeted Therapies in Pediatric Central Nervous System Tumors

Talloa, D., Triarico, S., Agresti, P., Mastrangelo, S., Attinà, G., Romano, A., Maurizi, P., & Ruggiero, A. (2022) · Cancers · doi:10.3390/cancers14174264 · Cited by 34

Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine

Goh, G., Schmid, R., Guiver, K., Arpornwirat, W., Chitapanarux, I., Ganju, V., Im, S., Kim, S., Dechaphunkul, A., Maneechavakajorn, J., et al. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002136 · Cited by 34

Cervical small cell neuroendocrine tumor mutation profiles via whole exome sequencing

Cho, S. Y., Choi, M., Ban, H.-J., Lee, C. H., Park, S., Kim, H. K., Kim, Y., Lee, Y. S., & Lee, J.-Y. (2016) · Oncotarget · doi:10.18632/oncotarget.14098 · Cited by 34

PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer

Mjøs, S., Werner, H. M., Birkeland, E., Holst, F., Berg, A., Halle, M. K., Tangen, I., Kusonmano, K., Mauland, K., Oyan, A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-10717-z · Cited by 27

Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma

Ezell, S. A., Wang, S., Bihani, T., Lai, Z., Grosskurth, S. E., Tepsuporn, S., Davies, B. R., Huszar, D., & Byth, K. F. (2016) · Oncotarget · doi:10.18632/oncotarget.7036 · Cited by 33

Overexpression of CLEC3A promotes tumor progression and poor prognosis in breast invasive ductal cancer

Ni, J., Peng, Y., Yang, F., Xi, X., Huang, X., & He, C. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s161311 · Cited by 33

Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma

Hou, G., Zhao, Q., Zhang, M., Fan, T., Liu, M., Shi, X., Ren, Y., Wang, Y., Zhou, J., & Lu, Z. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.07.075 · Cited by 33

BRCA1-associated protein inhibits glioma cell proliferation and migration and glioma stem cell self-renewal via the TGF-β/PI3K/AKT/mTOR signalling pathway

Wang, B., Chen, C., Liu, X., He, X. Q., Zhuang, H., Wang, D., & Chen, B. (2019) · Cellular Oncology · doi:10.1007/s13402-019-00482-8 · Cited by 33

Current cancer therapies and their influence on glucose control

Yim, C., Mansell, K. D., Hussein, N., & Arnason, T. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i7.1010 · Cited by 34

The Role of Genomics and Proteomics in Lung Cancer Early Detection and Treatment

Abbasian, M. H., Ardekani, A. M., Sobhani, N., & Roudi, R. (2022) · Cancers · doi:10.3390/cancers14205144 · Cited by 34

Resveratrol as an antitumor agent for glioblastoma multiforme: Targeting resistance and promoting apoptotic cell deaths

Shayan, S. K., Aliashrafzadeh, H., Dianat‐Moghadam, H., Rastegar‐Pouyani, N., Majidi, M., Zarei, M., Vastegani, S. M., Bahramvand, Y., Babaniamansour, S., & Jafarzadeh, E. (2023) · Acta Histochemica · doi:10.1016/j.acthis.2023.152058 · Cited by 33

Mechanistic insights into circRNA-mediated regulation of PI3K signaling pathway in glioma progression

Mafi, A., Khoshnazar, S. M., Shahpar, A., Nabavi, N., Hedayati, N., Alimohammadi, M., Hashemi, M., Taheriazam, A., & Farahani, N. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155442 · Cited by 33

Cytochrome c and cancer cell metabolism: A new perspective

Alshehri, B. (2024) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2024.102194 · Cited by 34

Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN

Zhu, H., Liu, Q., Tang, J., Xie, Y., Xu, X., Zhang, Y., Jin, K., & Sun, B. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000475648 · Cited by 32

Effect of silencing colon cancer-associated transcript 2 on the proliferation, apoptosis and autophagy of gastric cancer BGC-823 cells

Yu, Z., Wang, Z., Lee, K., Yuan, P., & Ding, J. (2017) · Oncology Letters · doi:10.3892/ol.2017.7677 · Cited by 32

Degradation of Sargassum crassifolium Fucoidan by Ascorbic Acid and Hydrogen Peroxide, and Compositional, Structural, and In Vitro Anti-Lung Cancer Analyses of the Degradation Products

Wu, T.-C., Hong, Y., Tsai, Y., Hsieh, S., Huang, R.-H., Kuo, C., & Huang, C.-Y. (2020) · Marine Drugs · doi:10.3390/md18060334 · Cited by 33

Rotundic Acid Induces DNA Damage and Cell Death in Hepatocellular Carcinoma Through AKT/mTOR and MAPK Pathways

Roy, G., Guan, S., Liu, H., & Zhang, L. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00545 · Cited by 32

Unveiling the role of PIK3R1 in cancer: A comprehensive review of regulatory signaling and therapeutic implications

Gupta, I., & Gaykalova, D. A. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.08.004 · Cited by 31

The Potential of PI3K/AKT/mTOR Signaling as a Druggable Target for Endometrial and Ovarian Carcinomas

Lengyel, C. G., Altuna, S. C., Habeeb, B. S., Trapani, D., & Khan, S. Z. (2019) · Current Drug Targets · doi:10.2174/1389450120666191120123612 · Cited by 31

PTPN3 Inhibits the Growth and Metastasis of Clear Cell Renal Cell Carcinoma via Inhibition of PI3K/AKT Signaling

Peng, X., Yang, J., Qiang, Y., Sun, R., Cao, Y., Zheng, L., Peng, L., Lang, Y., Mei, Y., Li, C., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-1142 · Cited by 30

Insights from the clinical phenotype of subjects with Laron syndrome in Ecuador

Guevara‐Aguirre, J., Bautista, C., Torres, C. D., Peña, G., Guevara, C., Palacios, C. S., Guevara, A., & Gavilanes, A. W. D. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09602-4 · Cited by 31

GHR is involved in gastric cell growth and apoptosis via PI3K/AKT signalling

Yan, H., Wang, H., Yin, Y., Zou, J., Xiao, F., Yi, L., He, Y., & He, B. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16160 · Cited by 31

Targeted Therapy for Chordoma: Key Molecular Signaling Pathways and the Role of Multimodal Therapy

Akinduro, O. O., Suárez-Meade, P., Garcia, D. P. M., Brown, D. A., Sarabia-Estrada, R., Attia, S., Gokaslan, Z. L., & Quiñones‐Hinojosa, A. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00814-5 · Cited by 31

Celastrol inhibits pathologic neovascularization in oxygen-induced retinopathy by targeting the miR-17-5p/HIF-1α/VEGF pathway

Zhao, K., Jiang, Y., Zhang, J., Shi, J., Zheng, P., Yang, C., & Chen, Y. (2022) · Cell Cycle · doi:10.1080/15384101.2022.2087277 · Cited by 32

Long Non-Coding RNAs (lncRNAs) as Regulators of the PI3K/AKT/mTOR Pathway in Gastric Carcinoma

Riquelme, I., Pérez-Moreno, P., Mora‐Lagos, B., Ili, C., Brebi, P., & Roa, J. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076294 · Cited by 32

Oncogenic and Therapeutic Targeting of PTEN Loss in Bone Malignancies

Xi, Y., & Chen, Y. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25159 · Cited by 31

Effect of evodiagenine mediates photocytotoxicity on human breast cancer cells MDA-MB-231 through inhibition of PI3K/AKT/mTOR and activation of p38 pathways

Xu, C., Wang, Q., Feng, X., & Bo, Y. (2014) · Fitoterapia · doi:10.1016/j.fitote.2014.10.010 · Cited by 32

Mechanisms and Application of Gas-Based Anticancer Therapies

Ji, P., Yang, K., Xu, Q., Qin, G., Zhu, Q., Qian, Y., & Yao, W. (2023) · Pharmaceuticals · doi:10.3390/ph16101394 · Cited by 31

Growth hormone abolishes beneficial effects of calorie restriction in long-lived Ames dwarf mice

Gesing, A., Al-Regaiey, K., Bartke, A., & Masternak, M. M. (2014) · Experimental Gerontology · doi:10.1016/j.exger.2014.08.010 · Cited by 30

Ginsenoside Rg3 Suppresses Proliferation and Induces Apoptosis in Human Osteosarcoma

Li, Y., Lu, J., Bai, F., Xiao, Y., Guo, Y., & Dong, Z. (2018) · BioMed Research International · doi:10.1155/2018/4306579 · Cited by 30

Columbamine suppresses hepatocellular carcinoma cells through down-regulation of PI3K/AKT, p38 and ERK1/2 MAPK signaling pathways

Lin, Z., Li, S., Guo, P., Wang, L., Zheng, L., Yan, Z., Chen, X., Cheng, Z., Yan, H., Cui, Z., et al. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.12.038 · Cited by 30

Therapeutic Innovations for Targeting Hepatoblastoma.

Garnier, A., Ilmer, M., Kappler, R., & Berger, M. (2016) · Anticancer Research · doi:10.21873/anticanres.11143 · Cited by 26

lncRNA DLEU1 contributes to tumorigenesis and development of endometrial carcinoma by targeting mTOR

Du, Y., Wang, L., Chen, S., Liu, Y., & Zhao, Y. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22835 · Cited by 30

Therapeutic challenges in renal cell carcinoma.

Penticuff, J. C., & Kyprianou, N. (2015) · Europe PMC (PubMed Central) · Cited by 29

CENPH Inhibits Rapamycin Sensitivity by Regulating GOLPH3-dependent mTOR Signaling Pathway in Colorectal Cancer

Wu, W., Wu, F., Wang, Z., Di, J., Yang, J., Gao, P., Jiang, B., & Su, X. (2017) · Journal of Cancer · doi:10.7150/jca.19940 · Cited by 29

Role of Piperine in Chemoresistance

Kumar, S., Bhandari, C., Sharma, P., & Agnihotri, N. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-812373-7.00013-9 · Cited by 30

Triangle of AKT2, miRNA, and Tumorigenesis in Different Cancers

Honardoost, M., & Rad, S. M. A. H. (2017) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-017-2657-3 · Cited by 29

Pathway perturbations in signaling networks: Linking genotype to phenotype

Li, Y., McGrail, D. J., Latysheva, N. S., Yi, S. S., Babu, M. M., & Sahni, N. (2018) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2018.05.001 · Cited by 30

Possible involvement of PI3K/AKT/mTOR signaling pathway in the protective effect of selegiline (deprenyl) against memory impairment following ischemia reperfusion in rat

Amini-Khoei, H., Saghaei, E., Mobini, G. R., Sabzevary‐Ghahfarokhi, M., Ahmadi, R., Bagheri, N., & Mokhtari, T. (2019) · Neuropeptides · doi:10.1016/j.npep.2019.101942 · Cited by 29

Downregulation of lncRNA ZEB1-AS1 Represses Cell Proliferation, Migration, and Invasion Through Mediating PI3K/AKT/mTOR Signaling by miR-342-3p/CUL4B Axis in Prostate Cancer

Ma, T., Chen, H., Wang, P., Yang, N., & Bao, J. (2020) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2019.3123 · Cited by 29

Pancreatic neuroendocrine neoplasms: Updates on genomic changes in inherited tumour syndromes and sporadic tumours based on WHO classification

Ishida, H., & Lam, A. K.-Y. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103648 · Cited by 29

Epidermal growth factor receptor pathway mutation and expression profiles in cervical squamous cell carcinoma: therapeutic implications

Bumrungthai, S., Munjal, K., Nandekar, S., Cooper, K., Ekalaksananan, T., Pientong, C., & Evans, M. F. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0611-0 · Cited by 29

Glucose-regulated protein 94 mediates cancer progression via AKT and eNOS in hepatocellular carcinoma

Huang, C., Batzorig, U., Cheng, W., Huang, M., Chen, W. Y., Wei, P., & Chang, Y. (2015) · Tumor Biology · doi:10.1007/s13277-015-4254-9 · Cited by 28

In search of AKT kinase inhibitors as anticancer agents: structure-based design, docking, and molecular dynamics studies of 2,4,6-trisubstituted pyridines

Trejo–Soto, P. J., Hernández‐Campos, A., Romo‐Mancillas, A., Medina‐Franco, J. L., & Castillo, R. (2017) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2017.1285724 · Cited by 28

Dual Abrogation of Mnk and Mtor: A Novel Therapeutic Approach for the Treatment of Aggressive Cancers

Lineham, E., Spencer, J., & Morley, S. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0062 · Cited by 28

Histone deacetylases inhibitor MS‐275 suppresses human esophageal squamous cell carcinoma cell growth and progression via the PI3K/Akt/mTOR pathway

Ma, S., Liu, T., Xu, L., Wang, Y., Zhou, J., Huang, T., Li, P., Liu, H., Zhang, Y.-T. Y., Zhou, X., et al. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28805 · Cited by 28

Identification of TC2N as a novel promising suppressor of PI3K-AKT signaling in breast cancer

Hao, X., Gao, L., Deng, X., Han, F., Chen, H., JIANG, X. H., Liu, W., Wang, D., Chen, J.-P., Cui, Z.-H., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1663-5 · Cited by 28

Bufalin reverses intrinsic and acquired drug resistance to cisplatin through the AKT signaling pathway in gastric cancer cells

Zhao, H., Zhao, D., Jin, H., Li, H., Yang, X., Zhuang, L., & Liu, T. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5426 · Cited by 28

Libidibia ferrea presents antiproliferative, apoptotic and antioxidant effects in a colorectal cancer cell line

Guerra, A. C. V. D. A., Soares, L. A. L., Ferreira, M. R. A., de Araújo, A. A., Rocha, H. A. O., de Medeiros, J. S., Cavalcante, R. S., & Júnior, R. F. D. A. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.05.123 · Cited by 30

Cross Talk Networks of Mammalian Target of Rapamycin Signaling With the Ubiquitin Proteasome System and Their Clinical Implications in Multiple Myeloma

Eichner, R., Fernández‐Sáiz, V., Targosz, B., & Bassermann, F. C. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.06.001 · Cited by 27

Rab1A promotes proliferation and migration abilities via regulation of the HER2/AKT-independent mTOR/S6K1 pathway in colorectal cancer

Cheng, Z., Shao, X., Xu, M., Wang, J., Kuai, X., Zhang, L., Wu, J., Zhou, C., & Mao, J. (2019) · Oncology Reports · doi:10.3892/or.2019.7071 · Cited by 27

Burn Ointment Promotes Cutaneous Wound Healing by Modulating the PI3K/AKT/mTOR Signaling Pathway

Gan, D., Su, Q., Su, H., Wu, L., Chen, J., Han, B., & Xiang, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.631102 · Cited by 27

Promising Anticancer Activities of Alismatis rhizome and Its Triterpenes via p38 and PI3K/Akt/mTOR Signaling Pathways

Jang, E., & Lee, J. (2021) · Nutrients · doi:10.3390/nu13072455 · Cited by 26

SPOP promotes CDCA5 degradation to regulate prostate cancer progression via the AKT pathway

Luo, Z., Wang, J., Zhu, Y., Sun, X., He, C., Cai, M., Ma, J., Wang, Y., & Han, S. (2021) · Neoplasia · doi:10.1016/j.neo.2021.08.002 · Cited by 27

Therapeutic potential of the PI3K inhibitor LY294002 and PARP inhibitor Talazoparib combination in BRCA-deficient triple negative breast cancer cells

Eskiler, G. G., & Öztürk, M. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110229 · Cited by 28

Piceatannol enhances Beclin-1 activity to suppress tumor progression and its combination therapy strategy with everolimus in gastric cancer

Huangfu, L., Wang, X., Tian, S., Chen, J., Wang, Y., Fan, B., Yao, Q., Wang, G., Chen, C., Han, J., et al. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2185-9 · Cited by 27

Association of PI3K/AKT/mTOR Pathway with Cancer and Its Therapeutic Implications

Saleem, S., Bashir, I., Khan, M. S., & Ahanger, M. S. (2025) · Springer eBooks · doi:10.1007/978-981-96-2763-9_3 · Cited by 3

Targeting the PI3K pathway in cancer: are we making headway?

Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033

Targeting the PI3K-AKT-mTOR signaling network in cancer

Khan, K. H., Yap, T. A., Li, Y., & Cunningham, D. (2013) · 癌症：英文版 · doi:10.5732/cjc.013.10057 · Cited by 217

PI3K/AKT/mTOR Signalling Pathways as Therapeutic Targets: From Biomarkers to Clinical Outcomes.

Greshnikov, V. (2026) · Journal of chemical health risks · doi:10.52783/jchr.v16.i2.13542

PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside

Alzahrani, A. S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.009 · Cited by 1,056